Annovis Bio Inc. announced on September 16, 2025, the publication of a new article in the peer-reviewed journal Biomolecules. The article describes the pharmacokinetic (PK) profile of a new crystal form of buntanetap and compares it to the old form across studies in mice, dogs, and humans. This publication provides full data to a broader audience.
The findings confirm that crystal buntanetap preserves the PK profile and metabolism of the original form, which is essential for the drug’s therapeutic efficacy. The new dihydrate crystal offers greater stability compared to the original anhydrous form. This validation supports the use of crystal buntanetap in clinical trials.
Alexander Morin, Ph.D., Director of Strategic Communications, stated that this publication validates the use of crystal buntanetap in clinical trials and reinforces the consistency and reliability of their lead asset. The new crystal form is currently being used in the pivotal Phase 3 clinical trial for early AD, and it extends the intellectual property protection of the compound into the 2040s.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.